Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration — Stella

Home/Macular Degeneration Choroidal Neovascularization/

View on ClinicalTrials.gov

Recruiting

Back to Macular Degeneration Choroidal Neovascularization trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

Hong Kong

Department of Ophthalmology, United Chrisitian Hospital, Hong Kong

Key details

Phase

Post-approval study

Sponsor

Hospital Authority, Hong Kong

Enrollment target

~40 participants

Started

August 2025

Primary completion

October 2026

Age range

50 Years and older

Last updated October 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.